EPO biomarkers are the new rage in the biotechnology industry. The main goal of EPO biomarkers is to provide vital information about various health risks and the response to these risks. Biomarkers are capable of providing essential information about the risks without causing any side effects. The latest version of EPO biomarkers is made up of more than one hundred and forty components. This new version has proved to be more effective than its predecessors. In April 2020, the biopharmaceutical company, Medicortex Finland Oy, registered the patent rights for its diagnostic kit technology at the EPO (European Patent Office).
With the increase in cases of multiple sclerosis (MS), diagnosis and treatment of this condition has become very difficult. Most of the patients are not able to identify the progression of their disease, and hence, they remain untreated for a lifetime. Multiple sclerosis is a very complex condition that generates a wide spectrum of symptoms. The increasing prevalence of MS has led to increasing in the number of MS-related mortality, increased disability weight, and rising health care costs. The introduction of new medications such as gene therapy and non-traditional approaches to cure MS has made detection and early treatment of this condition increasingly difficult. In June 2021, a group of researchers from the Dongduk Women’s University, Seoul carried out a clinical trial to determine the prevalence of asthma-related anemia in 230,000 volunteering children.
Poor price limiting rules across the world accompanied by the scarcity of quality testing centers in emerging countries can act as a stumbling block for the expansion of the EPO biomarkers market.
On the contrary, growing sedentary lifestyles and poor eating habits have increased the frequency of chronic renal illnesses and malignancies in emerging nations, which has created positive growth prospects for the EPO biomarkers market. In addition, the rising prevalence of end-stage renal illness and hematological disorders compounded with the patent renewals of market participants is driving the demand for the EPO biomarkers market.
In the territorial breakdown, the EPO biomarkers market in the North American region is foreseen to augment at a significant rate owing to the rising cases of cancer in the region. Almost 600,000 people died due to cancer in the U.S., as per the 2018 report released by the Centers for Disease Control and Prevention (CDC). In the same line, the Asia Pacific region is also boding well for the EPO biomarkers market due to the increasing incidences of hematological diseases coupled with the availability of cheaper therapy options.